• During the COVID-19 period, fewer patients with HCC presented to the multidisciplinary tumour board. • Globally, modification in the treatment strategy was observed in 13.1% of patients. • More than 21% of patients experienced a treatment delay >1 month in the COVID-19 period compared with 9.5% in 2019. • COVID-19 infection was the main reason for treatment delays in 2020. • In 2020, 7.1% of patients had a diagnosis of an active COVID-19 infection and 4/21 (19.1%) died.